Dr. Francesca Spada is a Medical Oncologist at the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumor, European Institute of Oncology (IEO IRCCS, Milan, Italy). She has been part of this team for the last eight years. Francesca completed her specialty in Medical Oncology in 2011 at the University of Sassari. She is involved in clinical management of patients affected by neuroendocrine neoplasms (NENs), educational activities in NENs, and she is also involved in NENs translational research projects. In January 2019, she plans to finish her PhD in Translation and Experimental Medicine at the University of Insubria (Varese, Italy), focusing on the development of mixed adeno-neuroendocrine carcinomas (MANECs). She is also responsible for the IEO Neuroendocrine Multidisciplinary Group activity as quality coordinator.
She is a member of the Italian Association of Medical Oncology (AIOM) while also serving on the AIOM Young Directive Board. She is a member of the Directive Board of the Italian Association of Neuroendocrine Tumors (Ita.NET). She is also member of the European Neuroendocrine Tumor Society (ENETS), the North American Neuroendocrine Society (NANETS), and the European Society of Medical Oncology (ESMO).
In the last three years, Francesca co-authored several peer-reviewed studies, in particular a notable Italian multicenter analysis of oxaliplatin-based chemotherapy in NET patients as a lead author, and an Italian multicenter study of octreotide and everolimus as first-line therapy in patients with well-differentiated NETs.
Expert View | 
5 min
|
2019 
5 min
